Kizuki Yuza

Dr. Kizuki Yuza


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2026 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
KYKizuki Yuza
Kizuki Yuza
JKJun Kawashima
Jun Kawashima
OCOdysseas P. Chatzipanagiotou
Odysseas P. Chatzipanagiotou
CHChristian Hobeika
Christian Hobeika
FAFederico Aucejo
Federico Aucejo
Tim PawlikTim Pawlik
Tim Pawlik
The prognostic impact of vascular resection in intrahepatic cholangiocarcinoma (iCCA) remains uncertain, particularly in the context of advanced disease requiring complex surgery. This study evaluated the association between vascular resection and long-term survival and examined how tumor biology, assessed with tumor burden score (TBS) and CA19-9, influenced outcomes. Patients who underwent upfront curative-intent hepatectomy for iCCA were identified from an international multi-institutional database. Multivariable Cox regression assessed overall (OS) and recurrence-free survival (RFS). Among patients undergoing vascular resection, biologic heterogeneity was explored using optimized TBS and CA19-9 cutoffs to define biologic risk subgroups. Among 1757 patients, 9.7% (n = 171) required major vascular resection. These patients were more likely to have bilateral tumors (29.2% vs. 21.3%), lymph node metastasis (33.9% vs. 24.8%), and T3/T4 tumors (57.3% vs. 27.6%) (all p < 0.05). Vascular resection was not an independent predictor of OS (aHR 1.11, 95% CI 0.82-1.51) or RFS (HR 1.02, 95% CI 0.81-1.27). Within the vascular resection cohort, higher TBS (aHR 1.11, 95% CI 1.03-1.19) and higher CA19-9 (log-transformed; aHR 1.16, 95% CI 1.02-1.32) were independently associated with worse OS. Five-year survival decreased stepwise from favorable to unfavorable biologic profiles. Patients with favorable biology demonstrated survival comparable to individuals undergoing hepatectomy without vascular resection. Major vascular resection did not independently worsen prognosis after iCCA hepatectomy. Instead, tumor biology-captured by TBS and CA19-9-was strongly associated with long-term outcomes, highlighting the importance of biologic risk stratification when considering vascular resection.

16 June 2026 in Cells
Verified
Journal Article
Open access
PDF file
KYKizuki Yuza
Kizuki Yuza
Tim PawlikTim Pawlik
Tim Pawlik
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related death worldwide, and first-line systemic treatment has shifted toward immune checkpoint inhibitor (ICI)-based combinations. Response is heterogeneous, and mechanistic interpretation has lagged behind clinical practice, leaving open the question of why some tumors respond while others do not. This review uses the cancer immunity cycle as an HCC-specific scaffold to map where anti-tumor immunity fails—across priming, trafficking, suppressive myeloid or stromal, and metabolic-hypoxic barriers—and interpret combination strategies and resistance through the dominant barrier each tumor presents. ICI monotherapy rescues only specific failure points within the cycle. Combination regimens may be more effective when they are matched to one or more dominant barriers, whereas response may fail when the selected partner addresses only a secondary barrier while the dominant ecological constraint remains intact. Resistance can be similarly organized into tumor cell autonomous, microenvironmental, treatment-induced, and etiology-specific layers, with disease etiology shaping both baseline immune ecology and therapy-context vulnerability. A mechanism-based, biomarker-guided, and etiology-aware framework may help move the field from broad empiricism toward precision immunotherapy, but it should be viewed as a conceptual and translational organizing model that requires prospective testing in biomarker-stratified studies.

27 March 2026 in Livers
Verified
Journal Article
Open access
PDF file
KYKizuki Yuza
Kizuki Yuza
MAMiho Akabane
Miho Akabane
Tim PawlikTim Pawlik
Tim Pawlik
Background: Intrahepatic cholangiocarcinoma (ICC) is an uncommon but increasingly recognized primary liver malignancy with a poor prognosis. Although surgical resection offers the only realistic opportunity for cure, recurrence is common and the optimal integration of surgery with systemic and liver-directed therapies continues to evolve. Summary: This review summarizes contemporary evidence on the diagnosis and multidisciplinary management of ICC with particular emphasis on surgical, systemic, locoregional, and transplant-based strategies. Cross-sectional imaging plays a central role in staging and assessing resectability including evaluation of vascular invasion and the future liver remnant. Upfront resection is appropriate for selected patients with resectable disease and preserved liver function, with margin-negative resection and lymphadenectomy remaining key oncologic goals. Systemic therapy continues to evolve with cytotoxic chemotherapy forming the backbone of treatment for advanced disease and immunotherapy and targeted agents demonstrating promise in biomarker-defined subgroups. Locoregional modalities such as hepatic arterial infusion therapy and radioembolization may provide disease control in liver-dominant ICC and are increasingly used within a multidisciplinary framework. Liver transplantation remains investigational but may offer favorable outcomes in highly selected early-stage disease.

4 June 2026 in HPB
Verified
Journal Article
Open access
KYKizuki Yuza
Kizuki Yuza
JKJun Kawashima
Jun Kawashima
Christian HobeikaChristian Hobeika
Christian Hobeika
MLMickael Lesurtel
Mickael Lesurtel
FAFederico Aucejo
Federico Aucejo
Tim PawlikTim Pawlik
Tim Pawlik
Accurate preoperative risk stratification remains essential for patients undergoing curative-intent hepatectomy for intrahepatic cholangiocarcinoma (iCCA) or hepatocellular carcinoma (HCC). Although the albumin-bilirubin (ALBI) score and AST-to-platelet ratio index (APRI) reflect hepatic reserve and fibrosis burden, respectively, their complementary value for predicting liver-related complications across primary liver malignancies remains poorly defined. A retrospective multi-institutional cohort study included 2668 patients who underwent curative-intent hepatic resection for iCCA or HCC (2000-2023). Multivariable logistic regression evaluated associations of ALBI and APRI with liver-related complications, post-hepatectomy liver failure (PHLF), and major complications. Discrimination was assessed using the area under the receiver operating characteristic curve (AUC) with bootstrap internal validation. Among 2668 patients, 392 (14.7%) developed liver-related complications. Both ALBI (OR 1.65, 95% CI 1.28-2.12) and APRI (OR 1.18, 95% CI 1.05-1.33) were independently associated with liver-related complications. The combined model achieved an AUC of 0.740 (optimism-corrected 0.733). ALBI and APRI also demonstrated differential associations across endpoints, with APRI more strongly associated with PHLF and ALBI more strongly associated with major complications. Preoperative ALBI and APRI were independently associated with liver-related complications after hepatectomy for iCCA and HCC, reflecting hepatic reserve and fibrosis-related injury.

20 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
KYKizuki Yuza
Kizuki Yuza
JKJun Kawashima
Jun Kawashima
MAMiho Akabane
Miho Akabane
Tim PawlikTim Pawlik
Tim Pawlik
The liver is an immunologically distinctive organ. Portal blood continuously delivers gut-derived antigens and microbial products, requiring hepatic immunity to balance surveillance with restraint. In hepatocellular carcinoma (HCC), this physiology is commonly overlaid by chronic injury, inflammation, and fibrosis, so the background liver forms part of the disease context in which the tumor microenvironment (TME) develops. This review synthesizes how cellular architecture, tumor-intrinsic programs, and structural, metabolic, and microbial conditions interact to shape immune evasion and heterogeneity. HCC provides the principal evidence base, with intrahepatic cholangiocarcinoma (iCCA) used as a structured, biologically distinct comparator. We organize therapies by the microenvironmental barriers they are intended to modify and distinguish established clinical efficacy from evidence that the proposed mechanisms mediate treatment benefit. Single-cell and spatial studies have resolved cellular states and spatial arrangements, including onco-fetal endothelial–myeloid neighborhoods and a macrophage–fibroblast boundary band separating lymphocyte-rich stroma from malignant tissue. These patterns operate within fibrotic and metabolically altered tissue and vary by etiology, spatial context, and tumor type. Vascular endothelial growth factor blockade with immune checkpoint inhibition and dual checkpoint blockade are established first-line options in advanced HCC. Chemo-immunotherapy is established in biliary tract cancer, and IDH1 inhibition has established efficacy in IDH1-mutant cholangiocarcinoma. Myeloid- and stroma-directed strategies, natural-product approaches, and engineered-cell therapies remain preclinical or early clinical. None of the pivotal trials tested whether the proposed microenvironmental mechanism mediated treatment benefit. The liver TME informs treatment selection without yet determining it.

22 August 2026 in HPB
Verified
Journal Article
Open access
YEYutaka Endo
Yutaka Endo
KYKizuki Yuza
Kizuki Yuza
JKJun Kawashima
Jun Kawashima
OCOdysseas Chatzipanagiotou
Odysseas Chatzipanagiotou
SWSelamawit Woldesenbet
Selamawit Woldesenbet
Tim PawlikTim Pawlik
Tim Pawlik